Completed PHASE1 INTERVENTIONAL 1-arm NCT05577624

A Study to Evaluate the Drug-drug Interaction Effect of Rifampin on the Pharmacokinetics of AMG 510 in Healthy Participants

An Open-label Study to Evaluate the Drug-drug Interaction Effect of Rifampin, a CYP3A4 Inducer, on the Pharmacokinetics of AMG 510 in Healthy Subjects

Sponsor: Amgen

Conditions Healthy Participants

Interventions AMG 510 Rifampin

Updated 6 times since 2022 Last updated: Mar 14, 2025 Started: Nov 5, 2019 Primary completion: Dec 1, 2019 Completion: Dec 1, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy Participants and is currently completed. Amgen leads this study, which shows 6 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Apr 2025 — Present [monthly]

Completed PHASE1
Mar 2025 — Apr 2025 [monthly]

Completed PHASE1
Dec 2024 — Mar 2025 [monthly]

Completed PHASE1
Sep 2024 — Dec 2024 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Nov 2022 — Jul 2024 [monthly]

Completed PHASE1

First recorded

Nov 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen

Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Madison, United States